August 16, 2011 08:08 ET

Pain Therapeutics Market Reached $22 Billion in 2010

ROCKVILLE, MD--(Marketwire - Aug 16, 2011) - has announced the addition of the new report "The Pain Market Outlook to 2016," to their collection of Diseases & Conditions market reports. For more information, visit

The heterogeneity of pain necessitates a wide range of analgesics with different modes of action and delivery methods. As such, many different classes of drugs co-exist in the pain market. However, despite the wide range of treatment options, pain remains inadequately managed and substantial market opportunities exist for developers in chronic pain and neuropathic pain.

The global pain market recorded sales of $22 billion in 2010, rising at a compound annual growth rate (CAGR) of 8.9% from 2005. This growth was supported by the presence of five blockbuster pain drugs -- OxyContin, Lyrica, Cymbalta, Celebrex and Lidoderm. However, as patent expiries loom, the global market value is set to contract to $18.7 billion by 2016.

The pain pipeline is vast, featuring over 200 drugs in clinical development. Chronic pain remains the most studied indication, although there remains strong interest in neuropathic pain and acute pain. Tapentadol ER has the greatest potential of any pipeline drug, with superior tolerability to OxyContin and potential efficacy in neuropathic pain.

Pfizer was the market-leading company in the global pain market, registering $6.4bn in sales in 2010. Collectively, the top five pain companies accounted for 76.1% of the global market. This dominance is set to wane as their pipelines will be unable to restore market share lost to generics and new product launches.

For more information, visit

About is the leading provider of global market intelligence products and services. With over 300,000 research reports from more than 700 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact